NLS Pharmaceutics To Proceed With Phase 3 Clinical Program For Mazindol ER For Treatment Of Narcolepsy Following FDA Review And IRB ApprovalOof Full Study Protocol
Portfolio Pulse from Bill Haddad
NLS Pharmaceutics has received approval from the FDA and IRB to proceed with Phase 3 clinical trials for Mazindol ER, a treatment for narcolepsy.
July 03, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NLS Pharmaceutics' stock may see positive movement following the approval of Phase 3 clinical trials for Mazindol ER.
The approval of Phase 3 clinical trials for a company's drug is a significant milestone, often leading to increased investor confidence and potential stock price appreciation. Given that NLS Pharmaceutics has received such approval for Mazindol ER, it is reasonable to expect a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100